A physician survey finds a gap between guidelines and real-world clinical practice in treatment intensification for ...

Discover the study supports the potential of neoadjuvant androgen deprivation therapy as an adjunctive therapy in HRLPC.

Prostate cancer is a health issue that impacts individuals worldwide, and choosing the best treatment can be difficult, given ...

Researchers conducted a retrospective study using data from 182 subjects with high-risk recurrent prostate cancers.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

Evan Y. Yu, MD, discusses how systemic therapy options for newly diagnosed metastatic hormone-sensitive prostate cancer ...

Although treatments like androgen deprivation therapy have been effective for early-stage prostate cancer, advanced stages, such as castration-resistant prostate cancer, present significant ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Discover Baduanjin, a traditional Chinese exercise, and a potential complementary therapy for patients with prostate cancer ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

A new study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has found that many cases of high-risk nonmetastatic hormone-sensitive prostate cancer may be more advanced than ...